EWTX Live signals | Maximize Profits with Getagraph.com

BUY 123754 min ago

@ $18.60

Issued: 14 Feb 2024 @ 12:04

Return: 0.16%

Previous signal: Feb 13 - 14:56

Previous signal: Sell

Return: 2.65 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 11:36):

Stats
Today's Volume	166 304
Average Volume	737 664
Market Cap	1.74B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.390 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.87
ATR14	$0.0490 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Morris Arlene	Buy	34 311	Stock Options (Right to buy)
2024-05-06	Morris Arlene	Buy	0
2024-05-01	Moore John R	Sell	5 208	Restricted Stock Units
2024-05-01	Moore John R	Buy	5 208	Common Stock
2024-05-02	Moore John R	Sell	1 956	Common Stock

INSIDER POWER
71.74
Last 96 transactions
Buy: 6 453 320 \| Sell: 592 683

Volume Correlation

Long: 0.21 (neutral)

Short: 0.20 (neutral)

Signal:(33.027) Neutral

Edgewise Therapeutics, Correlation

10 Most Positive Correlations
HCCI	0.952
FFNW	0.949
DSPG	0.939
STAY	0.923
TLGT	0.915
ISRG	0.911
TIL	0.911
SRTS	0.909
FSEA	0.908
SUMO	0.906

10 Most Negative Correlations
MMAC	-0.947
RNAZ	-0.944
CNSP	-0.933
NETE	-0.928
UXIN	-0.927
XPDI	-0.922
WINT	-0.916
AXDX	-0.913
SCPS	-0.911
CSSEN	-0.91

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Edgewise Therapeutics, Correlation - Currency/Commodity

0.13
( neutral )

0.08
( neutral )

0.00
( neutral )

0.51
( weak )

0.49
( neutral )

0.20
( neutral )

Edgewise Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.73M (0.00 %)
EPS:	$-1.570

FY	2023
Revenue:	$0
Gross Profit:	$-1.73M (0.00 %)
EPS:	$-1.570

FY	2022
Revenue:	$0
Gross Profit:	$-538 000 (0.00 %)
EPS:	$-0.290

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.140

Financial Reports:

No articles found.

Edgewise Therapeutics,

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.